| Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer TS Mok, YL Wu, MJ Ahn, MC Garassino, HR Kim, SS Ramalingam, ... New England Journal of Medicine 376 (7), 629-640, 2017 | 3391 | 2017 |
| Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab K Sato, H Akamatsu, E Murakami, S Sasaki, K Kanai, A Hayata, ... Lung cancer 115, 71-74, 2018 | 372 | 2018 |
| Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn, A Delmonte, ... Annals of Oncology 31 (11), 1536-1544, 2020 | 197 | 2020 |
| Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system M Hosokawa, H Kenmotsu, Y Koh, T Yoshino, T Yoshikawa, T Naito, ... PloS one 8 (6), e67466, 2013 | 194 | 2013 |
| Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer M Kimura, T Naito, H Kenmotsu, T Taira, K Wakuda, T Oyakawa, ... Supportive Care in Cancer 23, 1699-1708, 2015 | 177 | 2015 |
| Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune‐checkpoint inhibitors C Kurimoto, H Inaba, H Ariyasu, H Iwakura, Y Ueda, S Uraki, K Takeshima, ... Cancer science 111 (5), 1468-1477, 2020 | 128 | 2020 |
| Efficacy of osimertinib plus bevacizumab vs osimertinib in patients with EGFR T790M–mutated non–small cell lung cancer previously treated with epidermal growth factor receptor … H Akamatsu, Y Toi, H Hayashi, D Fujimoto, M Tachihara, N Furuya, ... JAMA oncology 7 (3), 386-394, 2021 | 127 | 2021 |
| Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer S Sugawara, JS Lee, JH Kang, HR Kim, N Inui, T Hida, KH Lee, T Yoshida, ... Annals of Oncology 32 (9), 1137-1147, 2021 | 117 | 2021 |
| The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV H Akamatsu, K Ninomiya, H Kenmotsu, M Morise, H Daga, Y Goto, ... International journal of clinical oncology 24, 731-770, 2019 | 112 | 2019 |
| Nivolumab induced radiation recall pneumonitis after two years of radiotherapy R Shibaki, H Akamatsu, M Fujimoto, Y Koh, N Yamamoto Annals of Oncology 28 (6), 1404-1405, 2017 | 98 | 2017 |
| Perioperative durvalumab for resectable non–small-cell lung cancer JV Heymach, D Harpole, T Mitsudomi, JM Taube, G Galffy, M Hochmair, ... New England Journal of Medicine 389 (18), 1672-1684, 2023 | 88 | 2023 |
| Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma … E Iwama, K Sakai, K Azuma, T Harada, D Harada, K Nosaki, K Hotta, ... Annals of Oncology 28 (1), 136-141, 2017 | 81 | 2017 |
| Detection of the T790M mutation of EGFR in plasma of advanced non–small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology … T Takahama, K Sakai, M Takeda, K Azuma, T Hida, M Hirabayashi, ... Oncotarget 7 (36), 58492, 2016 | 79 | 2016 |
| Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single‐institute study M Serizawa, Y Koh, H Kenmotsu, M Isaka, H Murakami, H Akamatsu, ... Cancer 120 (10), 1471-1481, 2014 | 79 | 2014 |
| Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial H Akamatsu, N Katakami, I Okamoto, T Kato, YH Kim, F Imamura, ... Cancer science 109 (6), 1930-1938, 2018 | 66 | 2018 |
| Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study A Ono, T Takahashi, K Mori, H Akamatsu, T Shukuya, T Taira, ... BMC cancer 13, 1-10, 2013 | 66 | 2013 |
| Immune‐related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non‐small cell lung cancer H Akamatsu, E Murakami, J Oyanagi, R Shibaki, T Kaki, E Takase, ... The Oncologist 25 (4), e679-e683, 2020 | 64 | 2020 |
| Progression of irreversible airflow limitation in asthma: correlation with severe exacerbations K Matsunaga, T Hirano, A Oka, A Tanaka, K Kanai, T Kikuchi, A Hayata, ... The Journal of Allergy and Clinical Immunology: In Practice 3 (5), 759-764. e1, 2015 | 63 | 2015 |
| Tarlatamab for patients with previously treated small-cell lung cancer MJ Ahn, BC Cho, E Felip, I Korantzis, K Ohashi, M Majem, O Juan-Vidal, ... New England Journal of Medicine 389 (22), 2063-2075, 2023 | 58 | 2023 |
| Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity AB Hanker, BP Brown, J Meiler, A Marín, HS Jayanthan, D Ye, CC Lin, ... Cancer cell 39 (8), 1099-1114. e8, 2021 | 55 | 2021 |
